Potentiation of antitumor effect of cyclophosphamide and hydrazine sulfate by treatment with the antidiabetic agent, 1-phenylethylbiguanide (phenformin).
It was shown that 1-phenylethylbiguanide (phenformin) administered orally to mice at a dose of 2 mg/day potentiated the antitumor effect of cyclophosphamide on transplantable squamous cell cervical carcinoma, hepatoma-22a and Lewis lung tumor, but did not alter the effect of cyclophosphamide on sarcoma-180 and L-1210. Oral administration of phenformin (5 mg/day) to rats with transplanted Walker 256 carcinoma enhanced the antitumor effect of hydrazine sulfate.
D000818:Animals; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006834:Hydrazines / Q000008:administration & dosage*; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010629:Phenformin / Q000008:administration & dosage*; D012510:Sarcoma 180 / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy
D006834:Hydrazines; D003520:Cyclophosphamide; D010629:Phenformin